250+ investors that invest in your industry and stage
Get 250+ investors tailored to your startup
  • Invest in your industry and stage
  • Emails & contact info included
  • Excel and CSV export
  • Automatically
Trusted by 3,000+ startups

Top 50 Life Science Startup Investors

A list of 50 angel investors and VC funds that invest in Life science startups. We rank investors based on the number of investments they made in Life science companies. This investor list updates every month.

Top 50 Life Science Startup Investors

Investor Life Science investments
ARCH Venture Partners 24
Sofinnova Partners 22
Northpond Ventures 20
Alexandria Venture Investments 20
Parkwalk Advisors 17
Novartis Venture Fund 17
Fifty Years 15
OrbiMed 15
RA Capital Management 14
Versant Ventures 13
SR One 13
Oxford Science Enterprises 13
UK Innovation & Science Seed Fund 13
Google Ventures 13
5AM Ventures 11
Horizons Ventures 11
Roche Venture Fund 11
8VC 11
MPM Capital 11
Hatteras Venture Partners 11
Atlas Venture 11
Third Rock Ventures 10
Takeda Ventures 10
Alix Ventures 10
DCVC 10
M Ventures 10
Lux Capital 10
KdT Ventures 10
Dementia Discovery Fund 10
Kurma Partners 10
Sahsen Ventures 9
Oxford Science Enterprises 9
Rev1 Ventures 9
New Enterprise Associates 9
Andreessen Horowitz 9
Casdin Capital 9
Civilization Ventures 9
JDRF T1D Fund 9
Vivo Capital 9
AbbVie Biotech Ventures 8
High-Tech Grunderfonds 8
Omega Funds 8
F-Prime Capital 8
Khosla Ventures 8
Archangels 8
Apple Tree Partners 8
iSelect Fund 8
Enterprise Ireland 8
Longwood Fund 8
Bioeconomy Capital 8
Find investors that fund startups like yours. Automatically.
Our algorithm will find investors that invest in your industry, stage, and geography.
Investor list
ARCH Venture Partners VC Fund · Chicago, Illinois, United States · 16 investments in the past 12 months
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, China, United Kingdom
Portfolio highlights
  • Accompany Health — Accompany Health provides comprehensive in-home care to patients who live in sometimes underserved regions. Accompany Health offers primary care services such as chronic illness management and treatment of new symptoms. They also assist in the organization and coordination of care. There will be no more waiting rooms or lines for another form.Accompany Health cultivates long-term connections with the people they serve so that they know, without a doubt, that the team is there for them at all hours of the day and night, year after year.
  • Basking Biosciences — Basking Biosciences is a startup that’s developing a therapy to restore blood flow to the brain during ischemic stroke, preventing hemorrhage and long-term damage.
  • Moonwalk Biosciences — Pioneering precision epigenetic medicines We are hiring passionate, talented moonwalkers. See our open roles. Walk with Us Our science By deeply profiling and targeting the epigenetic code, Moonwalk aims to reprogram cells to their healthy state, fundamentally enabling a new approach to how therapies are discovered and developed. First in the field Moonwalk is the
Sofinnova Partners VC Fund · Paris, Ile-de-France, France · 30 investments in the past 12 months
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • France, United States, United Kingdom
Portfolio highlights
  • GlycoEra — GlycoEra is a CustomGlycan platform that unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics.
  • Freya Biosciences — Freya Biosciences is a clinical-stage women’s health company pioneering a new class of microbial immunotherapies. It is based in Copenhagen and Boston.
  • DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
Northpond Ventures VC Fund · Bethesda, Maryland, United States · 7 investments in the past 12 months
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more
Investment focus
  • Biotechnology, Health Care, Life Science
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Totus Medicines — Applying revolutionary chemical biology technologies to create life-changing covalent therapeutics for untreatable diseases.
  • Aro Biotherapeutics — Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins.
  • Elephas — Elephas is a live tumor imaging company developing novel cancer diagnostic solutions to predict treatment outcomes and accelerate drug development.
Alexandria Venture Investments VC Fund · Pasadena, California, United States · 21 investments in the past 12 months
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, France, Canada
Portfolio highlights
  • Tome Biosciences — Tome Biosciences is a biotechnology company that develops programmable gene insertion technology. Using CRISPR, its technologies allow them to insert any genetic sequence of any size at any location into any genome.
  • Ability biologics — Ability develops innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases.
  • Remix Therapeutics — Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.
Parkwalk Advisors VC Fund · London, England, United Kingdom · 15 investments in the past 12 months
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more
Investment focus
  • Biotechnology, Health Care, Software
  • Seed, Series A, Series B
  • United Kingdom, United States, Philippines
Portfolio highlights
  • Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
  • Fresh Check — Fresh Check is a simple sticker that you put inside the packaging of food that changes colour when your food has actually gone off, not when the use-by date says so.
  • Wayland Additive — Wayland Additive Limited is a West-Yorkshire based company pushing the boundaries of electron beam 3D printing. Wayland’s goal is to develop, manufacture and sell metal Additive Manufacturing (“AM” – 3D printing) machines to industrial end-users such as major players in the aerospace and medical industries.
Novartis Venture Fund VC Fund · Basel, Basel-Stadt, Switzerland · 5 investments in the past 12 months
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
  • Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
  • Hepalink — Hepalink is a manufactures ultra-pure pipeline control systems based on semiconductors and pan-semiconductor liquid circuits.
Fifty Years VC Fund · San Francisco, California, United States · 7 investments in the past 12 months
WE BACK HEROES using technology to solve the world's biggest problems
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United States, Germany, Canada
Portfolio highlights
  • Gridware — Using remote telemetry and edge AI, Gridware wildfire prevention technology powers a grid that is smarter and more reliable than ever before.
  • BIOS — BIOS Health is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals.
  • Elicit — Automate time-consuming research tasks like summarizing papers, extracting data, and synthesizing your findings.
OrbiMed VC Fund · New York, New York, United States · 30 investments in the past 12 months
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series A, Series C
  • United States, China, Israel
Portfolio highlights
  • Tyra Biosciences — Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Tyra is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in orderto generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. Tyra is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7% of all cancers. Tyra’s lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer.
  • Forward Therapeutics — Forward Therapeutics idelivers blockbuster oral agents for chronic inflammatory conditions. Science that impacts patient care.
  • Odyssey Therapeutics — Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases
RA Capital Management VC Fund · Boston, Massachusetts, United States · 49 investments in the past 12 months
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, United Kingdom, China
Portfolio highlights
  • Tyra Biosciences — Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Tyra is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in orderto generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. Tyra is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7% of all cancers. Tyra’s lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer.
  • Dianthus Therapeutics — Dianthus Therapeutics is leading the next generation of complement antibody therapeutics with best-in-class potential to address high unmet medical needs for patients.
  • Astria Therapeutics — Catabasis Pharmaceuticals is a biopharmaceutical company located in Cambridge, Massachusetts focused on the discovery and development of innovative drugs to treat inflammatory conditions. Their platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatoryresponse. The Catabasis platform will lead to the development of a novel mechanism of action therapies to safely and effectively treat inflammatory diseases.
Versant Ventures VC Fund · Menlo Park, California, United States · 4 investments in the past 12 months
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • United States, Switzerland, Canada
Portfolio highlights
  • Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
  • Nexo Therapeutics — Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies.
  • Tentarix Biotherapeutics — Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology. The company develops a protein engineering platform designed for multispecific therapies.
SR One VC Fund · Cambridge, Massachusetts, United States · 5 investments in the past 12 months
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Avalyn Pharma — This does NOT display on the home page
  • Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
  • Odyssey Therapeutics — Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases
Oxford Science Enterprises VC Fund · Oxford, Oxfordshire, United Kingdom · 8 investments in the past 12 months
Oxford Sciences Innovation is the world’s largest university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companiestaking on challenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more
Investment focus
  • Health Care, Biotechnology, Software
  • Seed, Series A, Funding Round
  • United Kingdom, United States, Finland
Portfolio highlights
  • Navenio — Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons orwi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice.The company was founded in 2015 and is headquartered in Oxford, England.
  • Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
  • Oxford Quantum Circuits — Oxford Quantum Circuits developing technology using the power of quantum to do things which have never been achieved before, from enabling life-changing drug discoveries to developing new battery technologies.
UK Innovation & Science Seed Fund VC Fund · Harwell, Oxfordshire, United Kingdom · 16 investments in the past 12 months
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Funding Round, Series A
  • United Kingdom, United States
Portfolio highlights
  • MitoRx Therapeutics — Developing revolutionary mitochondrial-protective therapeutics which reverse mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration. MitoRx Therapeutics' first-in-class first-in-target platform has potential to arrest the progression of some of the most challenging diseases.
  • Oxford Space Systems — Oxford Space Systems is a multi-award-winning, record-breaking venture capital backed, space tech business that's developing a new generation of deployable antennas and space structures for the global satellite industry. Using both innovative design techniques such as origami and novel proprietary materials developed by the company, OSS'structures are lighter, less complex and lower cost than alternatives in commercial demand. Founded in late 2013, OSS set a record for the space sector with it's AstroTube Boom: the fastest development of a new product from concept to successful deployment on orbit in under 30 months. Today, the 18 strong and growing OSS team is a diverse mix of international graduates and experienced space industry professionals, with over 100 years of combined space sector experience. OSS investors include a small syndicate of UK venture capital funds together US based investors, Space Angels. Oxford Space Systems has successfully completed a number of UK government supported co-developments with leading European satellite builders as well straight commercial contracts in both Asia and the US. As part of its planned expansion, OSS move into its own custom facility at the Harwell Space Cluster in August 2018, giving it the largest clean room at the cluster. The facility will meet required security standards to undertake UK government defense & security contracts. .
  • Laverock Therapeutics — Laverock Therapeutics is developing a gene silencing platform for the creation of programmable, allogeneic cell therapies.
Google Ventures VC Fund · Mountain View, California, United States · 48 investments in the past 12 months
GV supports innovative founders moving the world forward.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series A, Series B, Seed
  • United States, United Kingdom, Canada
Portfolio highlights
  • StatusPro — StatusPro is a sports technology company that combines data with augmented and virtual reality to provide a suite of training and gaming products.
  • FlutterFlow — FlutterFlow is an online app builder that lets users easily build native apps. Build fully functional apps with Firebase integration, API support, animations, and more. Export your code or even easier deploy directly to the app stores!
  • Granata Bio — Granata Bio is a biopharma company focused on women's health and infertility. Our mission and focus is to create access for fertility patients by introducing new therapeutic solutions.
5AM Ventures VC Fund · Menlo Park, California, United States · 6 investments in the past 12 months
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, Switzerland, Canada
Portfolio highlights
  • Tyra Biosciences — Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Tyra is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in orderto generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. Tyra is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7% of all cancers. Tyra’s lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer.
  • Silence Therapeutics — Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetictoolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types.
  • Adverum Biotechnologies — At Adverum, we are driven to establish ocular gene therapy as a new standard of care for debilitating retinal diseases.
Horizons Ventures VC Fund · Hong Kong, Hong Kong Island, Hong Kong · 16 investments in the past 12 months
Investing in the deep science and technology that can propel humanity towards a radically better future.
Show more
Investment focus
  • Biotechnology, Artificial Intelligence, Software
  • Series A, Series B, Seed
  • United States, United Kingdom, Canada
Portfolio highlights
  • MioTech — MioTech is an artificial intelligence platform that empowers investment managers to better serve their clients in a world of complex data. By integrating and analyzing data from all types of sources, MioTech streamlines the entire investment process, creating an ultimate data-driven investing experience. MioTech has offices in Shanghai and HongKong.MioTech is backed by Horizons Ventures, ZhenFund, and prestigious individual investors around the world.
  • CellVoyant — We provide services to accelerate development of stem cell therapies. We make therapy development faster and more cost-effective.
  • Kimia Therapeutics — Generating a chemical atlas for treating human disease
Roche Venture Fund VC Fund · Basel, Basel-Stadt, Switzerland · 2 investments in the past 12 months
The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, United Kingdom, Spain
Portfolio highlights
  • DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
  • Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
  • Bonum Therapeutics — Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.
8VC VC Fund · San Francisco, California, United States · 36 investments in the past 12 months
8VC seeks to enable industry transformation. In a wave of creative destruction, they believe emerging platforms will replace the decades-old technology infrastructure behind many industries, promoting greater innovation and prosperity.
Show more
Investment focus
  • Software, Health Care, Artificial Intelligence
  • Seed, Series A, Series B
  • United States, Canada, Colombia
Portfolio highlights
  • LightBeam.ai — LightBeam.ai - zero trust data protection pioneer, converges & simplifies data security, privacy, & AI governance, so businesses can accelerate their growth in new markets with speed & confidence. Leveraging generative AI as a foundational technology, We tie together sensitive data cataloging, control, & compliance across structured, unstructured, & semi-structured data applications providing 360-visibility, risk remediation, & compliance with PCI, GLBA, GDPR, HIPAA among other regulations.
  • Rainbow — Rainbow Insurance offers flexible coverage that's 100% tailored for restaurants. Connect with a trusted advisor and get better coverage at the right price.
  • Harbor Health — Harbor Health is a multi-specialty clinic group that provides smarter health care using technology. The company co-creates a health path that is dedicated to knowing individuals' health goals with the guidance of specialists when needed. Harbor Health was founded in 2022 and is based in Austin, Texas.
MPM Capital VC Fund · Cambridge, Massachusetts, United States · 7 investments in the past 12 months
Powering Breakthroughs in Life Sciences
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series A, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • AstronauTx — AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.
  • Deka Biosciences — Deka BioSciences, Inc. is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.
  • ReCode Therapeutics — ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our pipeline of rare disease therapeutics uses optimized mRNA and gene correction with redosing capability.
Hatteras Venture Partners VC Fund · Durham, North Carolina, United States · 6 investments in the past 12 months
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Funding Round
  • United States, Canada
Portfolio highlights
  • 410 Medical — 410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina.
  • Myeloid Therapeutics — Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyteapproach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.
  • Veralox Therapeutics — Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
Atlas Venture VC Fund · Cambridge, Massachusetts, United States · 10 investments in the past 12 months
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Triveni Bio — Triveni Bio is pioneering a genetics-informed precision medicine approach to develop functional antibodies to treat immunological and inflammatory disorders.
  • Remix Therapeutics — Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.
  • Accent Therapeutics — Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth anddifferentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, they aim to translate extraordinary science into life-changing therapies for patients.
Third Rock Ventures VC Fund · Boston, Massachusetts, United States · 4 investments in the past 12 months
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States
Portfolio highlights
  • Flare Therapeutics — Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Our drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.
  • Rapport Therapeutics — Precision medicines to match the complexity of the human brain.
  • CARGO Therapeutics — CARGO Therapeutics develops CAR T-cell therapy to overcome cancer treatment resistance and address access barriers so that more patients can benefit from potentially curative therapies. The company is on a mission to outwit cancer by developing best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite commercially available autologousCARs advancements, these treatments are curative for less than half of all cancer patients. Furthermore, far too many patients are unable to access these potentially curative therapies due to other obstacles such as manufacturing, supply constraints, long turnaround times, and reimbursement barriers. CARGO's team is intensely focused on pursuing novel solutions to improve cancer treatment outcomes and experiences.
Takeda Ventures VC Fund · San Diego, California, United States · 2 investments in the past 12 months
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Funding Round
  • United States, United Kingdom, Israel
Portfolio highlights
  • Cerevance — Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle theearly onset of various neurological diseases.
  • OncoResponse — OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.
  • Larkspur Biosciences — Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.
Alix Ventures VC Fund · San Francisco, California, United States
Supporting early stage Life Science startups driving patient impact. Born from our collective experience as founders, we set out to build the fund we wanted to raise from....
Show more
Investment focus
  • Biotechnology, Health Care, Life Science
  • Seed, Series A, Pre-Seed
  • United States
Portfolio highlights
  • Xilis — Xilis is an oncology and precision health company that diagnoses cancer and finds the right treatment. The company uses “micro-organoids” to make thousands of 3D replicas of a patient’s tumor in about six days, which the company says can be used for testing for drug compatibility faster. It was founded in 2019 and is headquartered in Durham,North Carolina.
  • Zafrens — Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States.
  • Endpoint Health — Endpoint Health is a precision-first therapeutics company. By rewriting the molecule-first drug development model, we aim to deliver precision therapies that have the potential to improve outcomes for patients with immune-driven illnesses.
DCVC VC Fund · San Francisco, California, United States · 20 investments in the past 12 months
We are deep tech venture capital.
Show more
Investment focus
  • Software, Artificial Intelligence, Health Care
  • Seed, Series A, Series B
  • United States, Canada, United Kingdom
Portfolio highlights
  • Relay — Relay helps leaders run their teams more effectively by establishing the right workflows, running them on time, and automating tedious coordination.
  • Fourth Power — Fourth Power makes renewable energy an on-demand energy source through utility-scale, thermal battery technology. With the ability to provide flexible-duration energy storage, we can start small and grow with the grid to save consumers money and ensure a clean energy future.
  • Reality Defender — Reality Defender is deepfake detection done right. With billions of visual and audio assets indexed, we offer the most robust deepfake detection available.
M Ventures VC Fund · Amsterdam, Noord-Holland, The Netherlands · 11 investments in the past 12 months
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Seed
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
  • DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
  • Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.
Lux Capital VC Fund · New York, New York, United States · 24 investments in the past 12 months
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series A, Seed, Series B
  • United States, Canada, United Kingdom
Portfolio highlights
  • Sakana AI — We are creating a new kind of foundation model based on nature-inspired intelligence.
  • Coris — Coris helps Financial Services companies better manage small business risk by providing alternate credit quality data on merchants and constantly monitor businesses for changes in business quality
  • Atavistik Bio — Atavistik Bio is harnessing the power of protein-metabolite interactions to add a new lens to drug discovery.
KdT Ventures VC Fund · Austin, Texas, United States · 3 investments in the past 12 months
KdT Ventures is the standard for early-stage frontier science investing.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United States, Israel, Germany
Portfolio highlights
  • Andes — Andes empowers microbes to enable positive action against climate change.
  • Aperiam Bio — Aperiam Bio partners with enzyme engineers and distributors to create and share stabilized, solubilized, and catalytically optimized proteins. The company was founded in 2021 and is headquartered in Austin, Texas, United States.
  • SURGE Therapeutics — SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed.
Dementia Discovery Fund VC Fund · London, England, United Kingdom · 3 investments in the past 12 months
SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Seed, Series A, Funding Round
  • United States, United Kingdom, Israel
Portfolio highlights
  • Therini Bio — Therini Bio is developing novel therapeutics based insights into the role of fibrin in driving chronic innate immune activation.
  • AstronauTx — AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.
  • Violet Therapeutics — Violet Therapeutics is a healthcare company that operates in stealth mode.
Kurma Partners VC Fund · Paris, Ile-de-France, France · 8 investments in the past 12 months
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more
Investment focus
  • Health Care, Biotechnology, Pharmaceutical
  • Series A, Series B, Seed
  • France, Spain, Switzerland
Portfolio highlights
  • Poppins — Mila merges music, technology, and neuroscience to reshape therapy into a musical experience. We create musical games for children based on neurologic music therapy methods. These games are designed to address learning dissabilities like dyslexia, providing a digital treatment at home and helping identify these conditions. Behind these games, weleverage data science and new technologies to interpret learning, language, and motor performance into a cognitive score. Our goal is to improve the process for patients receiving treatment and to reaching the vast undiagnosed majority.
  • Shorla Pharma — Shorla Pharma is an Irish specialty pharmaceutical company. It is growing portfolio brings accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact.
  • Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
Sahsen Ventures VC Fund · Seattle, Washington, United States
Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.
Show more
Investment focus
  • Biotechnology, Health Care, Non Profit
  • Funding Round, Series A, Seed
  • United States, China, Ghana
Portfolio highlights
  • Monod Bio — Monod Bio l Simple. Powerful. Biosensors for Medicine & Biotech.
  • Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
  • Terray Therapeutics — Everything small molecule drug discovery should be.
Oxford Science Enterprises VC Fund · Oxford, Oxfordshire, United Kingdom
Oxford Science Enterprises a university-partnered venture firm, investing in early-stage life science, AI & software, and deep tech.
Show more
Investment focus
  • Biotechnology, Health Care, Software
  • Series A, Seed, Series B
  • United Kingdom, United States, The Netherlands
Portfolio highlights
  • Archangel Lightworks — Archangel Lightworks is integrating space and air assets using laser communication.
  • Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the neoantigen repertoire in cancer.
  • Quantum Motion — One Hundred Qubits is Interesting. One Million is World-changing
Rev1 Ventures VC Fund · Columbus, Ohio, United States · 9 investments in the past 12 months
Rev1 Ventures provides seed stage venture capital funding in Columbus, Ohio along with startup services, space, mentoring, and connections. Learn more!
Show more
Investment focus
  • Software, Health Care, Information Technology
  • Seed, Series A, Funding Round
  • United States, Germany
Portfolio highlights
  • Lentechs — CREATING A NEW VISION LENTECHS is a privately-held, clinical-stage, ophthalmic medical device company in Columbus, Ohio dedicated to improving vision at every stage of life through innovative design and breakthrough contact lens technology. LENTECHS is focused on developing a patented, first-of-its-kind line of soft, suspended contact lens designed to deliver exceptional, glasses-like vision at all
  • Basking Biosciences — Basking Biosciences is a startup that’s developing a therapy to restore blood flow to the brain during ischemic stroke, preventing hemorrhage and long-term damage.
  • Clarametyx Biosciences — Clarametyx Biosciences is a late preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms.
New Enterprise Associates VC Fund · Menlo Park, California, United States · 41 investments in the past 12 months
Foundational partners to ambitious founders at every stage of company-building.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series B, Series A, Series C
  • United States, India, China
Portfolio highlights
  • Perplexity AI — Perplexity is a search engine platform that uses artificial intelligence to provide large language models and search engines. The company's platform enables the development of beneficial artificial general intelligence, as well as an open-source environment that is accessible to the public, allowing clients to develop skills and knowledge inartificial intelligence.
  • Metronome — Metronome helps software companies launch, iterate, and scale their usage-based business models, with billing infrastructure that works at any size and stage.
  • Second Front Systems — The continuous accreditation and deployment of commercial software is crucial for U.S. national security missions. With Second Front Systems' Game Warden platform, you'll be achieving exactly that.
Andreessen Horowitz VC Fund · Menlo Park, California, United States · 111 investments in the past 12 months
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more
Investment focus
  • Software, Information Technology, Internet
  • Series A, Seed, Series B
  • United States, United Kingdom, Canada
Portfolio highlights
  • Metronome — Metronome helps software companies launch, iterate, and scale their usage-based business models, with billing infrastructure that works at any size and stage.
  • Ambience Healthcare — Experience what it feels like to never have to type or dictate another note again.
  • Mountaintop Studios — Mountaintop Studios is a game studio creating multiplayer games for players who crave a challenge.
Casdin Capital VC Fund · New York, New York, United States · 7 investments in the past 12 months
Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, France, China
Portfolio highlights
  • Octave — Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States.
  • ROME Therapeutics — ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier inbiology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.
  • Remix Therapeutics — Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.
Civilization Ventures VC Fund · San Francisco, California, United States · 7 investments in the past 12 months
DIGITAL HEALTH / AI DIGITAL HEALTH / AI GENE / CELL THERAPIES NASDAQ: RCKT GENE / CELL THERAPIES NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS SYNTHETIC
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United States, United Kingdom, Brazil
Portfolio highlights
  • DermBiont — Leading a Revolution in Dermatology
  • Aperiam Bio — Aperiam Bio partners with enzyme engineers and distributors to create and share stabilized, solubilized, and catalytically optimized proteins. The company was founded in 2021 and is headquartered in Austin, Texas, United States.
  • Range Biotechnologies — We're dedicated to making health monitoring a reality. We develop tools that capture the molecular state of individuals to prevent disease and improve health.
JDRF T1D Fund VC Fund · Boston, Massachusetts, United States · 3 investments in the past 12 months
The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Throughpartnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Funding Round
  • United States, Italy, Canada
Portfolio highlights
  • DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
  • SAB Biotherapeutics — A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems,rare conditions, long-term diseases and global pandemic threats.
  • Veralox Therapeutics — Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
Vivo Capital VC Fund · Palo Alto, California, United States · 15 investments in the past 12 months
Vivo Capital is a healthcare focused investment firm formed in 1996 that is currently making investments from its $1.4B Vivo Capital Fund IX into promising private healthcare companies and from its $635M Vivo Opportunity Fund into promising public healthcare companies.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series C, Series A
  • United States, China, Canada
Portfolio highlights
  • Tourmaline Bio — Tourmaline Bio is a clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients and prevent immune diseases.
  • Silence Therapeutics — Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetictoolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types.
  • Adverum Biotechnologies — At Adverum, we are driven to establish ocular gene therapy as a new standard of care for debilitating retinal diseases.
AbbVie Biotech Ventures VC Fund · North Chicago, Illinois, United States · 3 investments in the past 12 months
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Togetherwith its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, China, Italy
Portfolio highlights
  • Mozart Therapeutics — The company intended to focus on developing novel immune engagers.
  • Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
  • DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
High-Tech Grunderfonds VC Fund · Bonn, Nordrhein-Westfalen, Germany · 50 investments in the past 12 months
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 895.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 500 startups since 2005. Driven by their expertise, entrepreneurial spirit, and passion, its teamof experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry, and life sciences.To date, external investors have injected over EUR 2 billion into the HTGF portfolio via about 1,400 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Banking Group, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.
Show more
Investment focus
  • Software, Information Technology, Biotechnology
  • Seed, Series A, Funding Round
  • Germany, Switzerland, United States
Portfolio highlights
  • BTRY — BTRY is a spin-off of EMPA and ETH and is developing the industry's first energy-dense solid-state battery, using sophisticated semiconductor manufacturing technologies.
  • SKY ENGINE AI — About Sky EngineSky Engine is an advanced data science technology and research company that develops innovative software solutions to improve computer vision. The company markets the Sky Engine deep learning platform, which is the next-generation of self-learning AI system for image and video analysis applications. The company was founded as aresearch and scientific spin-off in UK.About Sky Engine PlatformThe Sky Engine evolutionary AI platform for the deep learning in virtual reality is designed to overcome the complex object recognition challenges of modern machine/computer vision. It represents the future of self-learning in artificial intelligence technology, supporting efficient and cost effective workflows. Many image recognition tasks require acquisition of large amounts of data and manual data labelling. Sky Engine is designed to replace that. Sky Engine efficiently drives self-learning processes and offers advanced features for object discrimination, workflow automation and adaptive deep learning. Sky Engine is designed for tomorrow’s requirements in advanced analytics and decision support enabling AI business transformation.About Sky Engine client solutionsSky Engine creates flexible and innovative AI vision solutions tailored to customer needs and supports a wide range of industries, providing systems for a variety of data science needs, ensuring business partners get greater value from existing equipment.
  • BOX ID Systems — BOX ID Systems develops and offers an end-to-end location & process mining solution to cost effectively track millions of logistics assets digitally throughout the industrial supply chain across Europe and the World - including site-to-site, on-premises and indoor buildings digital twin of supply chain processes. The system is built on aspecialized analytics software platform, sensorik tracking devices and efficient data-, device- and user-management tools, including functions to support process automation and optimization. Industrial and automotive production customers benefit from making their logistics processes more efficient and cost optimized, with 100% transparency within their critical processes throughout the entire supply chain.
Omega Funds VC Fund · Boston, Massachusetts, United States · 3 investments in the past 12 months
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series A, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • ARTBIO — ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports.
  • Upstream Bio — Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. Upstream Bio was founded in 2004 and was headquartered in the United States.
  • Bicara Therapeutics — Bicara enables access to the thriving innovation ecosystem which accelerates our development of therapies for cancer. Synergies between the Bicara teams in Boston and Bengaluru will pioneer breakthrough innovation.
F-Prime Capital VC Fund · Cambridge, Massachusetts, United States · 30 investments in the past 12 months
F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more
Investment focus
  • Health Care, Biotechnology, Medical
  • Series A, Series B, Series C
  • United States, United Kingdom, China
Portfolio highlights
  • ARTBIO — ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports.
  • T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .
  • Shinobi Therapeutics — Shinobi Therapeutics is a biotechnology business that is working on a novel class of immune-evasive iPSC-derived cell treatments.
Khosla Ventures VC Fund · Menlo Park, California, United States · 64 investments in the past 12 months
Khosla Ventures invests in companies that are bold, early and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs. Headquartered in Menlo Park, Calif., Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech,digital health, medtech and diagnostics, therapeutics and frontier technology.
Show more
Investment focus
  • Software, Health Care, Artificial Intelligence
  • Series A, Series B, Seed
  • United States, India, United Kingdom
Portfolio highlights
  • Recraft — The first generative AI design tool that lets users create and edit digital illustrations, vector art, icons, and 3D graphics in a uniform brand style.
  • Overmoon — Overmoon offers a growing collection of family-oriented rentals.
  • Moonwalk Biosciences — Pioneering precision epigenetic medicines We are hiring passionate, talented moonwalkers. See our open roles. Walk with Us Our science By deeply profiling and targeting the epigenetic code, Moonwalk aims to reprogram cells to their healthy state, fundamentally enabling a new approach to how therapies are discovered and developed. First in the field Moonwalk is the
Archangels VC Fund · Edinburgh, Edinburgh, City of, United Kingdom · 6 investments in the past 12 months
Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.
Show more
Investment focus
  • Software, Biotechnology, Health Care
  • Funding Round, Seed, Series A
  • United Kingdom, United States
Portfolio highlights
  • Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
  • 1inhaler — 1inhaler operates as a developer of drug delivery device.
  • Cytomos — Cytomos develops and provides integrated, predictive analytics systems for intelligent bioprocessing in biopharma and cell therapy domains.
Apple Tree Partners VC Fund · New York, New York, United States · 4 investments in the past 12 months
ATP, a global leader in life sciences venture capital, is developing the next generation of transformative biotechnology companies. ATP creates science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines. The firm provides flexible capital, strategicinsight, and operational resources to build sustainable, research-driven enterprises. ATP invests in its portfolio companies from seed stage through IPO and beyond and supports their management teams in strategic transactions and synergistic business combinations.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Seed
  • United States, Canada, United Kingdom
Portfolio highlights
  • Aulos Bioscience — Aulos Bioscience is a immuno-oncology company revolutionizing cancer care through the development of best-in-class IL-2 therapeutics. Learn more.
  • Ascidian Therapeutics — Ascidian is redefining the treatment of disease by rewriting RNA.
  • Deep Apple Therapeutics — Deep Apple Therapeutics is discovering new small-molecule therapeutics with unprecedented speed and exceptional acumen.
iSelect Fund VC Fund · St Louis, Missouri, United States · 5 investments in the past 12 months
Venture investing in Food, Health, and AgTech. A generational investment thesis. Food is Health is longevity
Show more
Investment focus
  • Biotechnology, Health Care, Agriculture
  • Seed, Series A, Series B
  • United States, Australia
Portfolio highlights
  • MEND — Mend is the scientifically proven way to heal and enhance your body faster.
  • Triplebar — Triplebar provides sustainability, biotechnology, and synthetic biology research.
  • Pluton Biosciences — The miniscule organisms Pluton Biosciences discover possess the power to create global change. Pluton quickly and inexpensively taps into the diverse world of bacteria, fungi and viruses to discover next-generation products for carbon sequestration, agriculture, pharmaceutical, biomaterials and bioremediation.Pluton Bioscience's discoveryprocess generates diverse commercialization options, including: Organisms (biological products), Small Molecule Chemistries (fermentable and non-fermentable) and New Traits (scale dependent).
Enterprise Ireland VC Fund · Dublin, Dublin, Ireland · 19 investments in the past 12 months
Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.
Show more
Investment focus
  • Software, Health Care, Information Technology
  • Funding Round, Seed, Series A
  • Ireland, United States, United Kingdom
Portfolio highlights
  • Cytidel — Cytidel helps security teams reduce breaches, save time, and stay secure. Vulnerability Management and Cyber Risk Management, and Threat Intelligence Specialists
  • GREYSCOUT — Safeguard your reputation and increase revenue with GreyScout, the scalable, always-on platform for fighting IP infringement and grey market sellers.
  • Positive Carbon — Positive Carbon provides an innovative solution for businesses to track, manage, and reduce food waste. With real-time analytics, CO2 calculation, and a comprehensive learning platform, we help you save costs and achieve sustainability goals. Request a demo today to start making a positive environmental impact.
Longwood Fund VC Fund · Boston, Massachusetts, United States · 2 investments in the past 12 months
Longwood creates and invests in science-based companies that develop novel solutions for important medical problems
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, United Kingdom
Portfolio highlights
  • Solu Therapeutics — Solu Therapeutics is a precision-medicine-focused company developing therapeutics to eliminate disease-driving cells.
  • Photys Therapeutics — Photys Therapeutics is a proprietary chimeric small molecules platform company, developing a new class of medicines for precise control of protein function.
  • Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
Bioeconomy Capital VC Fund · Seattle, Washington, United States
Bioeconomy Capital invests in early-stage companies with the goal of accelerating the biotechnology revolution. Based on its startup operational expertise, product development experience, and globally recognized strategic analysis, it has developed a blueprint for building and deploying technological capabilities that will become a criticalinfrastructure of the 21st-century economy.The company's proprietary blueprint is the distillation of the fund managers'​ five decades of combined experience in synthetic biology and other engineering fields and cannot be readily duplicated. Prior investments include Zymergen, Riffyn, Synthace, RoosterBio, Arzeda, Bellwether Bio, EdenWorks, and Lumen Biosciences.
Show more
Investment focus
  • Biotechnology, Life Science, Genetics
  • Series A, Series B, Seed
  • United States, United Kingdom
Portfolio highlights
  • Arzeda — Arzeda develops enzyme design technology that presents a new way of thinking about biocatalysis. The company was founded by David Baker and three senior members of his lab to commercialize and further develop its computational enzyme design technology.
  • Parse Biosciences — Parse Biosciences is providing researchers with the ability to perform single cell sequencing with unprecedented scale and ease. Learn more about how you can use the most scalable single cell platform on the market without the need for custom instrumentation.
  • Lumen Bioscience — We are transforming the way drugs are developed and what they cost.
Investors by industry
Investors by country
Investors in Life Science by country
Angel investors in Life Science by country
VC Funds in Life Science by country